Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kronos Bio, Inc. - Common Stock (NQ:KRON)

0.7052 -0.0092 (-1.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kronos Bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope 
From Kronos Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Kronos Bio: Q1 Earnings Insights
Via Benzinga
Expert Ratings for Kronos Bio
Via Benzinga
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs 
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in Upcoming Investor Conferences
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Changes to Board of Directors
From Kronos Bio, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 99 companies made new 52-week lows. 
Via Benzinga
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
From Kronos Bio, Inc.
Via GlobeNewswire
5 Most Expensive Health Care Stocks You Should Worry About
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial
From Kronos Bio, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
Kronos Bio Announces Participation in Upcoming Investor Conferences
From Kronos Bio, Inc.
Via GlobeNewswire
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell... 
Via Benzinga
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022
Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022 
From Kronos Bio, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.